Table 3 Perioperative outcomes, 90-day complications, and functional outcomes.

From: Single-port transvesical enucleation of the prostate (STEP) for benign prostatic hyperplasia: a comparative analysis of patients with large (80–150cc) and very large (>150cc) prostate volumes

Variables

LP

VLP

p-value

(n = 93)

(n = 86)

Perioperative outcomes

Length of stay (hours), median (IQR)

4.6 (3.7–5.9)

5 (3.8–6)

0.171

Outpatient procedure, n (%)

60 (91%)

48 (84.2%)

0.282

Incidental adenocarcinoma, n (%)

4 (4.3%)

2 (2.3%)

0.684

Days with Foley Catheter, median (IQR)

5 (4–7)

5 (3–7)

0.888

Opioid-free at discharge, n (%)

58 (62.4%)

73 (85%)

0.181

Blood transfusions, n (%)

0 (0%)

1 (1.2%)

0.48

90-day major postoperative complications, n (%)

1 (1%)

1 (1.2%)

1

90 days hospital readmission, n (%)

0 (0%)

0 (0%)

1

Failed trial of void, n (%)

2 (2.2%)

1 (1.23%)

1

Functional outcomes

Time to follow-up (months) included in follow-up analysis, median (IQR)

3.9 (3–7.1)

3.6 (3.1–6.3)

0.716

Time to last follow-up (months), median (IQR)

6.1 (3.3–12.2)

7.5 (3.4–12.4)

0.777

PSA (ng/mL), median (IQR)

0.87 (0.34–2.5)

0.78 (0.5–2.1)

0.61

 △PSA (ng/mL), median (IQR)

5.25 (2.8–8.2)

8.8 (4.4–19)

0.003

Postoperative IPSS score, median (IQR)

3 (1–6)

3 (1–7)

0.913

 △IPSS score, median (IQR)

14 (8–17)

13 (8–21)

0.336

Postoperative QoL score, median (IQR)

0 (0–1)

1 (0–1)

0.965

 △QoL score, median (IQR)

3 (2–5)

3 (2–5)

0.626

Postoperative Qmax (mL/s), median (IQR)

17.5 (11–27)

16 (10–25)

0.594

 △Qmax (mL/s), median (IQR)

−5 ((−9)–(−0.6))

−12 ((−19)–(−6))

0.141

Postoperative PVR (mL), median (IQR)

12.5 (0–33)

19 (0–54)

0.288

 △PVR (mL), median (IQR)

70 (0–388)

82 (21–231)

0.717

Postoperative SHIM score, median (IQR)

14 (5–21)

13 (5–16)

0.477

 △SHIM score, median (IQR)

0 ((−1)–(6))

0 ((−1)–(1))

0.421

Urinary continence status

Transient urinary incontinence, n (%)

2 (3.4%)

4 (7.5%)

0.272

 Urge, n

0

4

 Stress, n

0

0

 Mixed, n

2

0

Persistent urinary incontinence

  

1

 at 3 months, n (%)

0 (0%)

0 (0%)

 at 6 months, n (%)

0 (0%)

0 (0%)

 at 12 months, n (%)

0 (0%)

0 (0%)

  1. IQR Interquartile Range, BMI Body Mass Index, CCI Charlson Comorbidity Index, PSA Prostate Specific Antigen, IPSS International Prostate Symptom Score, QoL Quality of life, Qmax Maximum flow rate, PVR Post-void residual, SHIM Sexual Health Inventory for Men questionnaire Delta= Baseline – Post-operative parameters difference.
  2. Bold values indicate statistically significant differences between groups based on two-sided testing (p 0.05).
Back to article page